Imatinib Completed Phase 2 Trials for Scleroderma, Localized / Scleroderma, Systemic Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00479934Efficacy and Safety of Imatinib in Scleroderma